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Hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Weber-Rendu disease, is a rela-tively common “rare” vascular disease with an esti-mated prevalence of 1 in 5000–8000.1,2 Inheritance 
is autosomal dominant. Genetic findings include germline 
mutations primarily in ENG, encoding endoglin (HHT type 1, 
OMIM#187300), and ACVRL1 encoding activin receptor-like 
kinase-1 (HHT type 2, OMIM#600376), whereas muta-
tions in SMAD4 (juvenile polyposis/HHT overlap syndrome, 
OMIM#175050) are found only in a small proportion of cases, 
and mutations in GDF2, encoding the activin receptor-like 
kinase-1-ligand BMP9 (HHT5, OMIM#615506) so far in a few 
cases only.1,2 Mutations in these genes, all linked to TGFβ sig-
naling pathways, lead to the development of large visceral arte-
riovenous malformations (AVMs; mainly in the lungs, liver, and 
brain) and smaller telangiectasia of mucosa and skin, which are 
typically found on fingers, lips, tongue, buccal, and gastrointes-
tinal mucosa. The clinical phenotype is very variable but usually 
dominated by hemorrhages (ie, epistaxis and gastrointestinal 
bleeding) from these abnormal vascular structures and conse-
quences of chronic bleeding, primarily iron deficiency anemia.
Large AVM in the pulmonary circulation may cause right-left 
shunts associated with dyspnea, hypoxia, and can be the ori-
gin of preventable transient ischemic attacks, ischemic strokes, 
and cerebral abscesses. Hepatic AVMs can be associated with 
considerable intrahepatic shunting that can lead to high-output 
cardiac failure, portal hypertension, hepatic encephalopathy, 
and mesenteric ischemia, while cerebral AVMs may be caused 
with seizures and ischemic and hemorrhagic strokes.
The broad spectrum of clinical presentation of HHT, from 
asymptomatic patients with known germline mutations up to 
life-threatening conditions in others, is demanding specialized 
care to prevent future complications and to increase the quality 
of live and life-expectancy.
Patients with HHT are best managed in specialized centers 
with interdisciplinary multisystem teams including specialists of 
internal medicine, angiology, hematology, otolaryngology, gas-
troenterology, hepatology, radiology, neurology, genetics, and 
pediatrics. Next to these specialists, it is crucial to involve nurses, 
healthcare workers, psychologists, and patient advocates and to 
provide education programs for care givers and for patients and 
their families. This has been realized in recent years by imple-
menting the European Reference Networks (ERN) networks 
in countries of the European community, one of them having 
a working group for HHT, the VASCERN: https://vascern.eu/
expertise/rare-diseases-wgs/hht-wg/. Another example of such 
a network is Cure HHT: https://curehht.org, predominantly 
working in North America. However, not all countries are yet 
partners or have the possibility to become partners in these pro-
grams. Then, national reference centers, such as Bern University 
Hospital, Inselspital in Bern, Switzerland, have to elaborate pro-
grams themselves and/or try to get connected to the networks.
Taken the above into account, guidelines for diagnosis and 
treatment of HHT are extremely important and regular updates 
very helpful. Recently, an international panel from 15 countries, 
including 64 authors from the VASCERN and the Cure HHT 
published the Second International Guidelines on the Diagnosis 
and Management of Hereditary Hemorrhagic Telangiectasia in 
the Annals of Internal Medicine.3 This excellent guideline demon-
strates the successful multidisciplinary collaboration of medical 
experts, HHT patients, and patient advocates. The guidelines 
were developed using the AGREE (Appraisal of Guidelines 
for Research and Evaluation) II framework and the GRADE 
(Grading of Recommendations Assessment, Development, and 
Evaluation) methodology and focused on areas not previously 
addressed in guidelines, or where significant new information had 
been published. Six priority topics were identified and addressed:
• Epistaxis management
• Gastrointestinal bleeding management 
• Anemia and anticoagulation
• Liver venous malformations in HHT
• Pediatric care
• Pregnancy and delivery
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Other topics, such as clinical diagnosis of HHT, which is 
commonly based on the Curaçao criteria,4 diagnosis and man-
agement of cerebral vascular malformations or of pulmonary 
AVMs were not reassessed. Here, recommendations of the First 
International HHT Guidelines remain valid. All currently valid 
recommendations are nicely summarized in a detailed table at 
the beginning of the article.
While international and multidisciplinary collaborations 
in the past have helped to define a good standard of care for 
HHT patients,5,6 the Second International HHT Guidelines 
add an important value on the screening recommendations 
for nonsymptomatic HHT patients, especially in the pediatric 
age.3,7 The input of patients and patient advocates in this area 
is an innovative and strong aspect and resulted in proposing 
brain MRI in children to identify AVM, a diagnostic approach 
which was apparently favored more by patients than by medical 
experts.
In summary, the Second International Guidelines for the 
Diagnosis and Management of HHT provide practical evi-
dence-based guidance for clinicians and expert centers. It will help 
to further improve management of HHT patients and harmonize 
the diagnostics and therapeutic procedures internationally.
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